Sensitivity and specificity of different exercise oscillatory ventilation definitions to predict 2-year major adverse cardiovascular outcomes in chronic heart failure patients
Non Peer-reviewed author version


DOI: 10.1016/j.ijcard.2022.05.041
Handle: http://hdl.handle.net/1942/37331
Sensitivity and specificity of different exercise oscillatory ventilation definitions to predict 2-year major adverse cardiovascular outcomes in chronic heart failure patients

Gustavo dos Santos Ribeiro, Luís Fernando Deresz, Elisabetta Salvioni, Dominique Hansen, Piergiuseppe Agostoni, Marlus Karsten

PII: S0167-5273(22)00753-7
DOI: https://doi.org/10.1016/j.ijcard.2022.05.041
Reference: IJCA 30324

To appear in: International Journal of Cardiology

Received date: 6 April 2022
Revised date: 17 May 2022
Accepted date: 18 May 2022

Please cite this article as: G. dos Santos Ribeiro, L.F. Deresz, E. Salvioni, et al., Sensitivity and specificity of different exercise oscillatory ventilation definitions to predict 2-year major adverse cardiovascular outcomes in chronic heart failure patients, International Journal of Cardiology (2022), https://doi.org/10.1016/j.ijcard.2022.05.041

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Elsevier B.V. All rights reserved.
Sensitivity and specificity of different exercise oscillatory ventilation definitions to predict 2-year major adverse cardiovascular outcomes in chronic heart failure patients

Gustavo dos Santos Ribeiro1, Luís Fernando Deresz2, Elisabetta Salvioni3, Dominique Hansen4, Piergiuseppe Agostoni3,5, Marlus Karsten1,6,7

1 Programa de Pós-Graduação em Ciências da Reabilitação, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.
2 Departamento de Educação Física, Universidade Federal de Juiz de Fora (UFJF), Governador Valadares, Brazil.
3 Centro Cardiologico Monzino, IRCCS, Milan, Italy.
4 Hasselt University (UHASSELT), Faculty of Rehabilitation Sciences, BIOMED/REVAL, Hasselt, Belgium / Heart Centre Hasselt, Jessa Hospital, Hasselt, Belgium.
5 Department of Clinical Sciences of Community Health, Cardiovascular Section, University of Milano, Milano, Italy.
6 Departamento de Fisioterapia, Universidade do Estado de Santa Catarina (UDESC), Florianópolis, Brazil.
7 Programa de Pós-Graduação em Fisioterapia, UDESC, Florianópolis, Brazil.

Authorship statement
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Correspondence author
Marlus Karsten, Centro de Ciências da Saúde e do Esporte, Universidade do Estado de Santa Catarina (UDESC), Rua Pascoal Simone 358, CEP 88080-350, Florianópolis, SC, Brazil.
E-mail: marlus.karsten@udesc.br

Funding
This study was financed in part by the Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

Conflict of Interest Statement
The authors declare that there is no conflict of interest.
Sample CRediT author statement

**Gustavo Ribeiro**: Conceptualization, Methodology, Formal analysis, Writing - Original draft preparation. **Luís Fernando Deresz**: Conceptualization, Methodology, Writing - Original draft preparation. **Elisabetta Salvioni**: Resources, Writing - Review & Editing. **Dominique Hansen**: Writing - Review & Editing, Supervision. **Piergiuseppe Agostoni**: Resources, Writing - Review & Editing, Supervision. **Marlus Karsten**: Conceptualization, Methodology, Writing - Review & Editing, Project administration.
Abstract

Background: Exercise oscillatory ventilation (EOV) shows a four-fold greater risk of adverse events. This study aims to analyze the sensitivity and specificity of three EOV diagnostic definitions to predict adverse outcomes at a 2-year follow-up and to compare its EOV prevalence and relations with the patient’s profile.

Methods: Cardiopulmonary exercise tests from 233 heart failure patients were analyzed. Two blinded reviewers used a semiautomated software to identify EOV cases pattern according to the definitions of Ben-Dov, Corrèa, and Leite. Data were grouped in EOV-positive or EOV-negative according to each definition. Baseline characteristics, EOV prevalence, relative risk, sensitivity, and specificity to predict 2-years of major adverse cardiovascular outcomes were analyzed.

Results: The Corrèa definition led to the best prediction of 2-year major cardiovascular adverse outcomes (HR 2.46 [1.16 to 5.25]; p = 0.019, AUC = 0.618; p = 0.007). EOV prevalence was 17.2%, 17.2%, and 9.4% applying Ben-Dov, Corrèa, and Leite definition, respectively. The main clinical differences between EOV-positive and EOV-negative patients were: MECKI score and VE/VCO₂ slope (all definitions), and BNP levels (Ben-Dov and Leite). BNP levels were correlated with amplitude (rho = 0.255; p = 0.033) and cycle length (rho = 0.388; p = 0.002).

Conclusion: Corrèa definition was the only one that exhibited the capacity to predict major adverse cardiovascular outcomes at a 2-year follow-up. Regardless of its definition, EOV was more often prevalent in patients with a greater MECKI score and VE/VCO₂ slope values.

Keywords
Cardiology, Cardiovascular Diseases, Cardiopulmonary Exercise Test, Periodic Breathing, Prognosis.
1. Introduction

Exercise oscillatory ventilation (EOV) is an abnormal ventilatory pattern observed in chronic heart failure (HF) patients and is associated with disease severity and worse prognosis [1-3]. Cornelis et al. [4] reported a four-fold greater risk of adverse cardiovascular events in HF EOV-positive patients compared to their counterparts without EOV. Rovai et al. [5] highlighted that the presence of EOV is associated with a lower 2-year survival in HF patients with reduced or mid-range left ventricular ejection fraction, regardless of age and gender.

Although current evidence reinforces its predictive value, the EOV prevalence in HF is still controversial. Cornelis et al. [6] identified nine different EOV definitions based on EOV length and amplitude. It is not surprising that these different definitions lead to a wide range of EOV reported incidence, from 7 to 58% of HF patients [2, 6].

Although the American Heart Association has proposed the Corrà definition to screen for EOV cases [7], there is no consensus on the best EOV definition [4, 8]. Ingle et al. [9] were the first to evaluate the impact of different definitions on the prevalence and prognosis within EOV-positive patients. A similar prevalence between the Corrà and Leite definitions was observed (25 vs. 31%). However, EOV cases identified by the Corrà definition exhibited a greater hazard ratio (HR 6.3 [1.6 to 25.2]) to all-cause 12-month death than EOV cases identified by Leite definition (HR 4.9 [2.6 to 18.2]).

The different options to determine the EOV, due to the lack of standardization, compromises the clinical applicability of EOV. Albeit likely, it is unclear whether and to what extent the different definitions exhibit distinct sensitivities and specificities to detect EOV, and predict adverse outcomes. Among all the definitions available, we chose to compare Ben-Dov, Corrà, and Leite definitions because these definitions have different conceptual criteria in their development (e.g., high amplitude vs. longer duration) and have been frequently utilized in studies on EOV. These features may be linked to the HF aetiology (e.g., left or right HF) or clinical markers of hemodynamic impairment.

Therefore, this study aims to analyse the sensitivity and specificity to predict major adverse cardiovascular outcomes in a 2-year follow-up in HF patients, using three diagnostic definitions that apply distinct criteria to screen this phenomenon, and to compare the EOV prevalence and the clinical patient profile.

2. Methods

2.1 Study design

Retrospective anonymized single-centre data from 500 cardiopulmonary exercise tests (CPETs) performed between 2011 and 2014, and with a follow-up of at least 2 years, were analyzed. This study was approved by the Research Ethics Committee from the main author (referee 3.516.801/2019) according to current ethical standards.

2.2 Data sampling
CPETs of HF patients aged 40 to 90 years were included. Data from patients who performed a short CPET (< 6 minutes [10, 11]), with a too short registration (< 90 seconds) of the minute ventilation (VE) at rest, or tests that did not allow to apply the EOV definitions (corrupted file) were excluded. Patients with a follow-up < 2 years were also excluded.

2.3 Exercise test protocol

CPETs followed the hospital routine [12]. Briefly, a personalized ramp protocol was performed on an electronically braked cycle ergometer (Erg 800S; Sensor Medics, Yorba Linda, CA) [5, 13]. All subjects were instructed to perform a maximal effort (exercise peak near to 10 min). The tests were stopped when patients reported fatigue or in the presence of any cardiac abnormalities. The breath-by-breath data were collected and analysed using the 20-s smoothing average (Vmax® 12-3A Series, CareFusion, Yorba Linda, CA).

The highest 20-s averaged oxygen uptake (VO₂) value registered was considered as the VO₂PEAK. The VE/VCO₂ slope, a marker of ventilatory efficiency, was measured by applying the V-slope method, which is defined as the linear relationship between VE and carbon dioxide production (VCO₂), excluding the first minute of exercise and the period above the respiratory compensation point [5]. All measures were done following the hospital’s expertise.

2.4 Clinical profile and MECKI score

The patient’s clinical variables were obtained directly from the hospital’s medical record. Data on body mass index, New York Heart Association (NYHA) functional classification, left ventricular ejection fraction (LVEF), right ventricular systolic pressure (RVSP), blood hemoglobin, and B-type natriuretic peptide (BNP) levels were recorded. All variables were collected on the day of the CPET or within the week before it. The MECKI score was used for calculating the risk of chronic systolic HF, estimated from six independent predictors (% of VO₂PEAK predict, VE/VCO₂ slope, blood hemoglobin, sodium, left ventricular ejection fraction, and modification of diet in renal disease [MDRD]) [14].

2.5 EOV definitions

The EOV was determined by the combined characteristics of the ventilatory pattern (amplitude, cycle length, and/or oscillatory time) according to the definitions of Ben-Dov [15], Corrà [16], and Leite [17]. Figure 1 shows the EOV-positive ventilatory pattern and illustrates the minimum of oscillatory cycles or duration recommended for each definition.

INSERT FIGURE 1
2.6 EOV identification

Two blinded reviewers used a semiautomated tool to identify EOV cases in a standardized way. The software EASY-EOV tool 1.0 is an open-access application developed to allow the EOV analysis from CPET raw data of any system (LabVIEW, National Instruments, US). In a validation study, a high intra-rater (k ≥ 0.82) and inter-rater (k ≥ 0.83) reliability was observed (unpublished data).

2.7 Follow-up data

Follow-up data were recorded by the hospital service from the completion of the CPET until the registration of death or a cardiovascular procedure – limited to 2-years for all patients. Cardiovascular death, urgent heart transplantation, or the need for left ventricular assist device implantation were included as major adverse cardiovascular outcomes. Subjects without cardiovascular death or need for cardiac procedures, and who had clinical follow-up less than 1 year after CPET, were excluded.

2.8 Statistical analysis

Data were separated in EOV-positive vs. EOV-negative patients according to each definition. To assess normality of data distribution, we used the Kolmogorov–Smirnov test. Baseline characteristics were compared between groups by the Mann-Whitney test or Fisher’s exact test (EOV-positive vs EOV-negative) and Kruskal-Wallis test (EOV-positive between Ben-Dov, Corrà, and Leite)’s Q test and the McNemar post hoc were applied to compare the prevalence of EOV across different definitions. Furthermore, the interaction between EOV characteristics (amplitude, cycle length, and total oscillation time) and blood BNP levels was assessed by Spearman's correlations (rho).

All patients were followed for two years. The risk of major adverse cardiovascular outcomes was calculated for each EOV definition. The sensitivity and specificity to predict major adverse cardiovascular outcomes were estimated by the Receiver-Operating Characteristic (ROC) curve. All baseline variables were inserted as possible predictors in the univariate model (removed variable if \( p > 0.1 \) or collinearity > 0.3) [9]. Multivariable Cox proportional-hazards regression analysis was used with the backward method to identify the best predictive model (entered variable if \( p < 0.05 \)).

3. Results

Among 500 patients who performed a baseline CPET, 443 were HF patients. Of them, sixty-one records had less than 90 seconds of VE recording at rest, and 149 patients had too short or no clinical follow-up after CPET; these cases were excluded, leading to a study population of 233 cases. Table 1 shows the sample characteristics. EOV
prevalence was 17.2% (Ben-Dov), 17.2% (Corrà), and 9.4% (Leite). Ben-Dov and Corrà definitions identified 40 EOV cases each. Both definitions exhibited a greater prevalence than EOV cases identified by Leite ($p < 0.01$).

**INSERT TABLE 1**

EOV patients had a worse functional class, MECKI score, ventilatory efficiency (VE/VCO₂ slope), and lower maximal workload, regardless of EOV definition. There was no difference in clinical characteristics among EOV-positive groups when calculated by the definitions of Ben-Dov, Corrà and Leite ($p > 0.05$). EOV-positive cases identified by the definitions of Ben-Dov and Leite presented higher levels of blood BNP than HF patients without EOV. Low to moderate correlations between BNP levels and amplitude ($\rho = 0.255; p = 0.033$) or cycle length ($\rho = 0.388; p = 0.002$) were found. No association with total oscillation time was observed ($\rho = -0.104; p = 0.229$).

Among all EOV cases, 16 patients were exclusively identified by the definition of Corrà and 12 patients by the definition of Ben-Dov. Both definitions shared 22 EOV cases. Leite’s definition shared 15 positive cases with Corrà’s definition and 19 with Ben-Dov’s definition. Only one EOV patient was identified just by the definition of Leite. The overlap of EOV cases is presented in the Figure 1S. Regarding isolated diagnosis, blood BNP levels were greater when EOV was identified by the definition of Ben-Dov vs. the definition of Corrà (720 [411 to 1,067] vs. 260 [80 to 677] pg/mL; $p = 0.019$).

The relative risk for 2-year major adverse cardiovascular outcomes was significant applying Corrà’s definition (2.9 [1.6, 5.2]; $p < 0.001$), and Ben-Dov’s definition (1.9 [1.0, 3.7]; $p = 0.047$). However, Corrà’s definition was the only one that showed a significant probability to predict 2-year major adverse cardiovascular outcomes (Table 2).

**INSERT TABLE 2**

Supplemental Table 1S shows the potential predictors for major adverse cardiovascular outcomes (univariate analysis). Four variables were entered in the predictive model after multivariate Cox analysis (R²-adjusted = 0.184; $p < 0.001$). Only two variables were significantly predictive: Corrà’s definition (HR 2.46 [1.16 to 5.25]; $p = 0.019$) and age (HR 1.07 [10.3 to 1.12]; $p = 0.002$).

4. Discussion

The number of HF patients identified as EOV-positive ranged from 9.4 to 17.2% according to the applied definition. There was no difference in EOV prevalence (40 EOV cases) when applying Ben-Dov’s vs. Corrà’s definition. Of these 40 cases identified by the Ben-Dov and Corrà criteria, only 22 cases were identified by both criteria,
while the other 18 cases were identified exclusively by the Ben-Dov or by Corrà criteria. Moreover, the Corrà definition allowed us to identify EOV cases with the greatest 2-years major adverse cardiovascular outcome rate. In contrast, the blood BNP levels were greater in cases identified exclusively by Ben-Dov’s definition. Furthermore, a low-to-moderate correlation between blood BNP levels and amplitude or cycle length was observed.

To our knowledge, Ingle et al. [9] were the only that investigated the impact of different EOV diagnostic definitions on prognosis. They evaluated 240 HF patients applying Corrà and Leite definitions. There was no difference in EOV prevalence in both definitions (Corrà: 25% and Leite: 31%). However, Ingle et al. [9] observed that EOV-positive cases identified by Corrà’s definition were associated with a higher all-cause mortality at 1-year (HR 5.2 [2.8 to 9.9]; p < 0.001) in comparison to the cases identified by Leite’s definition (HR 4.8 [2.8 to 8.8]; p < 0.001).

In the present study, we found a lower EOV prevalence by all definitions, as well as a lower sensitivity to predict adverse outcomes applying the Corrà criteria, in comparison with other studies [9, 17]. Furthermore, Ben-Dov’s and Leite’s definitions did not show a sufficient sensitivity to predict 2-year major adverse cardiovascular outcomes.

The difference between our and previous study outcomes could be related to: the different baseline characteristics (our sample was older and with lower VO$_{2}$PEAK), the difference in follow-up time (24 vs 12 months), and the use of a semiautomated tool to identify EOV cases rather than manual scoring and/or visual interpretation (less subjective).

Our findings differ from other studies that used the Leite’s definition to identify EOV cases. In the original study, Leite et al. [17] observed a 30% EOV prevalence and a 3-times greater risk for premature death within 2 years in patients with heart transplantation indications (4P = 07 [1.34 to 6.54]; p < 0.01). Similarly, Vainshelboim et al. [18] found a higher prevalence (54%) and hazard ratio for major cardiac-related events at 5 years (HR 2.2 [1.2 to 4.1]; p = 0.011) applying Leite’s modified criteria.

Regarding Corrà’s methodology, the results are contradictory. The original study reported an EOV prevalence slightly lower than ours (12%) [16]. Nevertheless, Guazzi et al. [19] found a higher EOV prevalence in HF patients with a reduced (35%) and preserved ejection fraction (32%), beyond the greater hazard rate to overall mortality at four years (HR 2.0 [1.3 to 3.1]; p < 0.001 and 5.9 [2.1 to 16.9], p < 0.001). It should be noted that the exercise tests were performed both on a treadmill and cycle ergometer, making further inferences unfeasible since the specificity of the exercise mode can produce different physiological responses. In this sense, Guazzi et al. [19] observed 25% EOV-positive cases among tests performed on a cycle ergometer and 41% of EOV-positive cases among tests done on a treadmill.

Another point to be considered is the use of dichotomous EOV detection: EOV-positive or EOV-negative. As the EOV pathophysiology remains unknown [1, 3, 18], it is plausible to consider that the amplitude and/or length of each cycle differs from one patient to another, even with a confirmed EOV diagnosis by two or three definitions (by Corrà and Ben-Dov, for example). The clinical impact of this variation is yet unknown. It seems that the cycle
amplitude would be related to hemodynamic impairments such as circulatory delay [20], a lower ventilatory efficiency [21], and higher blood BNP levels [21]. Thus, higher amplitudes would be related to worse outcomes in EOV patients. Nonetheless, this hypothesis yet needs to be confirmed.

Our data show the EOV-positive patients diagnosed by Ben-Dov’s and Leite’s definition have higher blood BNP levels than those identified by Corrà’s definition, albeit with a lower mortality. Yamauchi et al. [21] also found a positive correlation between cycle amplitude and blood BNP levels when applying Leite’s definition ($r = 0.615; p = 0.007$). However, they did not provide an explanation for this finding. An essential factor that may have influenced blood BNP levels is the right ventricular impairment, commonly seen in HF superimposed by pulmonary hypertension. Leuchte et al. [22] found that high blood BNP levels were directly related to high pulmonary capillary wedge pressures, pulmonary vascular resistance, and right atrial pressure, and were inversely correlated with cardiac index or VO$_{2\text{peak}}$. Indeed, Murphy et al. [20] observed an association between right ventricular ejection fraction and both amplitude ($r = -0.68; p < 0.001$) or cycle length ($r = -0.48; p = 0.02$), suggesting that these parameters would be related to a worse hemodynamic function in EOV-positive patients.

This is the first study that investigated the predictive capacity of three definitions for EOV with totally different conceptual characteristics: Ben-Dov, Corrà, and Leite. Indeed, Ben-Dov proposed the presence of two consecutive cycles with 30-60s of length and a cycle magnitude of near to 25% of the average VE for EOV diagnosis [15]. Corrà proposed that the oscillation would need to be present in at least 60% of total exercise time, with an amplitude above 15% of the VE at rest [16]. Finally, Leite proposed that EOV would be characterized by at least three regular oscillations with a minimal amplitude above 5 L/min [17].

In brief, Ben-Dov’s and Leite’s definitions imply a shorter oscillation time, but a larger amplitude compared to the Corrà’s definition. It is unknown how these definitions are related to the patient hemodynamic impairment, albeit it is possible to speculate that a higher ventilation amplitude suggests a greater hemodynamic impairment [20, 21]. Nevertheless, the oscillation time seems to have a greater probability to predict adverse outcomes, which possibly would justify the better sensitivity of the Corrà’s definition. Accordingly, the reasons behind the cessation of EOV during exercise, albeit at present unknown, are of major importance. The idea that EOV ceased during exercise due to the capability to improve cardiac output, or to divert more blood to the exercising muscles, both leading to an improved peripheral oxygen delivery (which in its turn allows reducing the metabo -and chemoreflex sites of activation) are attractive and maybe the link between the observed difference in EOV prognosis and definition.

At present, the EOV definition described by Corrà [16], i.e., oscillation presence of at least 60% of loaded exercise with a minimal amplitude above 15% of VE at rest, seems to be the best choice to link EOV to prognosis.
4.1 Limitations

The present study has a few limitations which need to be acknowledged. Firstly, our sample size was small as limited in the number of major adverse cardiovascular outcomes, which may be related to the optimal treatment offered in a high-level cardiology centre. In this regard, bigger studies with a larger HF population that includes different phenotypes are definitively essential. Secondly, we re-analyzed CPET previously done in a single centre with mainly a low-ejection fraction HF phenotype. Therefore, our data should not be applied to different HF populations such as in mid-range or preserved ejection fraction patients [5].

5. Conclusion

The Corrà definition for EOV was the only one that exhibited the capacity to predict major adverse cardiovascular outcomes at a 2-year follow-up. The choice of EOV definition seems to affect the number of identified cases (ranging from 9.4 to 17.2%). Regardless of the definition, EOV was more often prevalent in patients with a greater MECKI score and VE/VCO₂ slope values. There were no differences in the clinical characteristics among EOV-positive groups. The positive correlation of blood BNP levels with amplitude and cycle length, the main features of the Ben-Dov and Leite definitions, suggests a link between these features with a clinical impairment marker.
References


Figure legends

Fig. 1. EOV-positive ventilatory pattern. EOV, exercise oscillatory ventilation. VE, minute ventilation. CPET, cardiorespiratory exercise test. SD, standard deviation.
Table 1. Clinical characteristics stratified by EOV definition

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EOV-positive</td>
<td>EOV-negative</td>
<td>EOV-positive</td>
</tr>
<tr>
<td>Sample, n (%)</td>
<td>40 (17.2)</td>
<td>193 (82.9)</td>
<td>40 (17.2)</td>
</tr>
<tr>
<td>Male gender, n (%)</td>
<td>35 (87.5)</td>
<td>156 (80.8)</td>
<td>31 (77.5)</td>
</tr>
<tr>
<td>NYHA class III-IV, n (%)</td>
<td>22 (55.0)*</td>
<td>67 (34.7)</td>
<td>22 (55.0)*</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>32.9 [30.2 – 36.4]</td>
<td>32.7 [32.0 – 35.2]</td>
<td>32.8 [32.0 – 35.3]</td>
</tr>
<tr>
<td>RVSP, mmHg</td>
<td>36.0 [33.0 – 46.0]</td>
<td>35.0 [32.0 – 37.0]</td>
<td>39.0 [37.0 – 46.0]</td>
</tr>
<tr>
<td>MECKI score, %</td>
<td>8.1 [6.0 – 11.5]*</td>
<td>3.7 [2.9 – 4.8]</td>
<td>7.4 [4.8 – 12.6]*</td>
</tr>
<tr>
<td>VE/VCO₂ slope</td>
<td>36.3 [32.9 – 40.3]*</td>
<td>29.6 [28.8 – 30.6]</td>
<td>36.0 [32.0 – 40.0]*</td>
</tr>
<tr>
<td>Major adverse outcome, n (%)</td>
<td>10 (25.0)</td>
<td>25 (13.0)</td>
<td>13 (32.5)**</td>
</tr>
</tbody>
</table>

Continuous data are expressed as median [95% confidence interval (CI)] and categorical data as absolute (n) and relative (%) frequencies. EOV, exercise oscillatory ventilation. EOV-positive, patients with a confirmed diagnosis. EOV-negative, patients with a negative diagnosis. NYHA, New York Heart Association. LVEF, left ventricular ejection fraction. RVSP, right ventricular systolic pressure. BNP, B-type natriuretic peptide. CPET, cardiopulmonary exercise test. VO_{2peak}, peak oxygen uptake. VE/VCO₂, minute ventilation-carbon dioxide production. *p < 0.05 Mann-Whitney Test (EOV-positive vs EOV-negative). **p < 0.01 Fisher's exact test (EOV-positive vs EOV-negative).
Table 2. Sensitivity and specificity to predict 2-year major cardiovascular adverse outcomes.

<table>
<thead>
<tr>
<th>Definition</th>
<th>AUC</th>
<th>95% CI</th>
<th>p-value</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben-Dov</td>
<td>0.567</td>
<td>0.487 to 0.647</td>
<td>0.100</td>
<td>28.57</td>
<td>84.85</td>
</tr>
<tr>
<td>Corrà</td>
<td>0.618</td>
<td>0.533 to 0.702</td>
<td>0.007</td>
<td>37.14</td>
<td>86.36</td>
</tr>
<tr>
<td>Leite</td>
<td>0.545</td>
<td>0.479 to 0.611</td>
<td>0.179</td>
<td>17.14</td>
<td>91.92</td>
</tr>
</tbody>
</table>

EOV, exercise oscillatory ventilation. AUC, area under the ROC curve. CI, confidence interval.
Author Agreement Form – International Journal of Cardiology

Manuscript Title: Sensitivity and specificity of different exercise oscillatory ventilation definitions to predict 2-year major adverse cardiovascular outcomes in chronic heart failure patients

List of all Authors: Gustavo S Ribeiro, Luís Fernando Deresz, Elisabetta Salvioni, Dominique Hansen, Piergiuseppe Agostoni and Marlus Karsten

Corresponding Author: Marlus Karsten (marlus.karsten@udesc.br)

This statement is to certify that all authors have seen and approved the manuscript being submitted, have contributed significantly to the work, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the International Journal of Cardiology.

We attest that the article is the Authors' original work, has not received prior publication and is not under consideration for publication elsewhere. We adhere to the statement of ethical publishing as appears in the International of Cardiology (citable as: Shewa LG, Rosano GMC, Henein MY, Coats AJS. A statement on ethical standards in publishing scientific articles in the International Journal of Cardiology family of journals. Int. J. Cardiol. 170 (2014) 253-254 DOI:10.1016/j.ijcard.2013.11).

On behalf of all Co-Authors, the corresponding Author shall bear full responsibility for the submission. Any changes to the list of authors, including changes in order, additions or removals will require the submission of a new author agreement form approved and signed by all the original and added submitting authors.

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. If there are no conflicts of interest, the COI should read: “The authors report no relationships that could be construed as a conflict of interest”.

Journal Pre-proof
Highlights

- Exercise oscillatory ventilation is a phenomenon associated with a worse prognosis.
- There is no consensus on the best EOV definition to be applied.
- EOV prevalence is higher when Ben-Dov or Corrè definitions are applied.
- BNP levels are associated with amplitude and cycle length.
- Corrè definition has the better capacity to predict 2-year mortality.
Figure 1

Kaplan-meier survival analysis

Survival probability (%)

Follow-up (days)

Overall
EOV -
EOV +

<table>
<thead>
<tr>
<th>Days</th>
<th>Overall</th>
<th>EOV -</th>
<th>EOV +</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>233</td>
<td>193</td>
<td>40</td>
</tr>
<tr>
<td>90</td>
<td>229</td>
<td>190</td>
<td>39</td>
</tr>
<tr>
<td>180</td>
<td>225</td>
<td>188</td>
<td>37</td>
</tr>
<tr>
<td>270</td>
<td>222</td>
<td>185</td>
<td>37</td>
</tr>
<tr>
<td>360</td>
<td>217</td>
<td>181</td>
<td>36</td>
</tr>
<tr>
<td>450</td>
<td>212</td>
<td>178</td>
<td>34</td>
</tr>
<tr>
<td>540</td>
<td>206</td>
<td>175</td>
<td>31</td>
</tr>
<tr>
<td>630</td>
<td>201</td>
<td>173</td>
<td>28</td>
</tr>
<tr>
<td>720</td>
<td>198</td>
<td>171</td>
<td>27</td>
</tr>
</tbody>
</table>

Figure 1